NEWAMSTERDAM PHARMA CO N.V.
NAMS evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $2.66B
- Lead Asset:
- obicetrapib (Phase 3)
What it means
What to watch
Prepared research question
What matters most for NAMS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NAMS
NEWAMSTERDAM PHARMA CO N.V. (NAMS) is a late-stage biopharmaceutical company developing oral, non-statin medicines, primarily obicetrapib, for cardiovascular disease and exploring its potential in Alzheimer's disease and diabetes.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 8 clinical trials for NEWAMSTERDAM PHARMA CO N.V..
NEWAMSTERDAM PHARMA CO N.V. (NAMS) is a late-stage biopharmaceutical company developing oral, non-statin medicines, primarily obicetrapib, for cardiovascular disease and exploring its potential in Alzheimer's disease and diabetes.
- Cash & equivalents of $424.2M as of 2026-06-30 [sec].
- Total revenue of $3.7M and net income of -$64.1M as of 2026-06-30 [sec].
- Shareholders' equity of $631.4M as of 2026-06-30 [sec].
- Phase 3 PREVAIL trial expected to complete by end of 2027 if interim analysis continues [sec_mda · as of 2026-08-05].
- Enrollment completed in March 2026 for Phase 3 REMBRANDT trial (323 patients) [sec_mda · as of 2026-08-05].
What works
- Strong cash position of $424.2M as of 2026-06-30 provides runway for ongoing trials [sec].
- Multiple Phase 3 trials (PREVAIL, REMBRANDT, RUBENS) are underway, indicating a robust late-stage pipeline [sec_mda · as of 2026-08-05].
- Exploration of obicetrapib in Alzheimer's disease and diabetes could open additional large markets [sec_mda · as of 2026-08-05].
What to weigh
- Net income of -$64.1M as of 2026-06-30 reflects ongoing operating losses with no approved product revenue [sec].
- Total revenue of only $3.7M as of 2026-06-30 indicates minimal commercial activity [sec].
- PREVAIL trial may be stopped early for efficacy or futility, creating binary outcome risk [sec_mda · as of 2026-08-05].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2021-12-15 · Phase3_Start: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying Therapies — Initiation of a key Phase 3 trial for obicetrapib in cardiovascular disease.
- 2022-07-25 · Phase3_Start: A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying Therapies — Second Phase 3 trial for obicetrapib in patients with familial hypercholesterolemia.
- 2023-11-11 · Phase1_Start: A Study to Evaluate the Effect of Daily Doses of Obicetrapib Tablets on the Pharmacokinetics of Atorvastatin Calcium Tablets or Rosuvastatin Calcium Tablets in Healthy Adult Subjects — Phase 1 drug-drug interaction study with statins.
- 2024-03-01 · Phase3_Start: A Placeb — Initiation of another Phase 3 trial (details truncated in source).
Risks & what to watch (3)›
Key risks
- No approved products — Company has no approved products; all revenue is minimal ($3.7M as of 2026-06-30) [sec].
- PREVAIL interim analysis risk — PREVAIL trial may be stopped early for efficacy or futility, creating binary outcome risk [sec_mda · as of 2026-08-05].
- Operating losses — Net loss of -$64.1M as of 2026-06-30 indicates ongoing cash burn [sec].
What to watch
- PREVAIL interim analysis results and potential early stop [sec_mda · as of 2026-08-05].
- Initiation of new Alzheimer's disease clinical trial for obicetrapib expected in 2026 [sec_mda · as of 2026-08-05].
- Completion of REMBRANDT and RUBENS Phase 3 trials [sec_mda · as of 2026-08-05].
- Presentations at ESC Congress 2026 (August 2026) [news · published 2026-08-26].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run NEWAMSTERDAM PHARMA CO N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEWAMSTERDAM PHARMA CO N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.12 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
0 buys · 7 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
168
Total value held
$3.83B
| Holder | Shares | Value |
|---|---|---|
| frazier life sciences management, l.p. | 16,943,774 | $542.4M |
| capital world investors | 11,109,034 | $355.6M |
| ra capital management, l.p. | 9,550,191 | $305.7M |
| fcpm iii services b.v. | 9,198,900 | $294.5M |
| fmr llc | 8,765,811 | $280.6M |
| bain capital life sciences investors, llc | 7,306,566 | $233.9M |
| wellington management group llp | 5,115,818 | $163.8M |
| deerfield management company, l.p. | 4,264,789 | $136.5M |
| viking global investors lp | 4,203,567 | $134.6M |
| polar capital holdings plc | 2,831,607 | $90.6M |
Showing top 10 of 168 institutional holders of NEWAMSTERDAM PHARMA CO N.V.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 8.3%
- Days to cover
- 8.6
- Shares short
- 8,047,048
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NAMS short interestGovernance
Frequently asked questions
What is the AI investment thesis for NEWAMSTERDAM PHARMA CO N.V.?
NEWAMSTERDAM PHARMA CO N.V. (NAMS) is a late-stage biopharmaceutical company developing oral, non-statin medicines, primarily obicetrapib, for cardiovascular disease and exploring its potential in Alzheimer's disease and diabetes.
What is NEWAMSTERDAM PHARMA CO N.V.'s lead drug candidate?
NEWAMSTERDAM PHARMA CO N.V.'s most advanced tracked candidate is obicetrapib (Phase 3) for Dyslipidemias; Healthy Volunteers; Antioxidant Absorption.
Who is the CEO of NEWAMSTERDAM PHARMA CO N.V.?
Dr. Michael Harvey Davidson FACC, Facp., M.D. is the chief executive officer of NEWAMSTERDAM PHARMA CO N.V. (NAMS).
Where is NEWAMSTERDAM PHARMA CO N.V. headquartered?
NEWAMSTERDAM PHARMA CO N.V. (NAMS) is headquartered in Naarden, Netherlands.
What therapeutic areas does NEWAMSTERDAM PHARMA CO N.V. focus on?
NEWAMSTERDAM PHARMA CO N.V. develops therapies across Oncology, Cardiovascular, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.